The participants in this clinical trial were randomized 1:1 in the treatment and placebo arms of the study titled, “randomized, single-blind, placebo-controlled study to evaluate the safety of the Lipid Sciences’ selective delipidation system, PDS-2, in subjects with acute coronary syndrome (ACS).” Patients currently enrolled in the trial will have completed their scheduled plasma collection and re-infusion treatments by the end of January 2008.
Dr Lewis Meyer, president and CEO of Lipid Sciences, said: “The FDA approved protocol for this study permitted Lipid Sciences to enroll a maximum of 30 patients based on the expectation that there would be a drop-out rate of up to 33%. The unusually high retention rate of 92% that we have experienced in this trial has allowed the company to gather sufficient data based upon the current enrollment of 28 patients.”